NL-OMON41740CompletedPhase 4
The effect of Ivacaftor in CF patients with a class III mutation - TICTAC II study
niversitair Medisch Centrum Utrecht0 sites16 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 16
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 2 to 99 (—)
Inclusion Criteria
- •CFTR genotype associated with residual CFTR function;
- •Already had a rectal biopsy to produce an organoid;
- •Start a treatment with Ivacaftor;
- •Male and female patients, aged 6 years or older on the date of informed consent;
- •Signed informed consent form (IC), and where appropriate, signed assent form.
Exclusion Criteria
- •Use of curcumin and or genistein at start or within two weeks prior to start of the study;
- •Inability to follow instructions of the investigator.
Investigators
Similar Trials
Completed
Not Applicable
The effect of Ivacaftor in CF patients with a class III mutatioNL-OMON26309niversity Medical Center Utrecht (UMCU)10
Completed
Not Applicable
Ivacaftor in French Patients With Cystic Fibrosis and a G551D MutationCystic FibrosisNCT02194881Assistance Publique - Hôpitaux de Paris57
Completed
Phase 2
Safety Study of Ivacaftor in Subjects With Cystic FibrosisCystic FibrosisNCT00457821Vertex Pharmaceuticals Incorporated39
Completed
Not Applicable
Pharmacokinetic interactions between ivacaftor and cytochrome P450 3A4 inhibitors in cystic fibrosis patients and healthy controlsmucoviscoidosis10083624Cystic fibrosisNL-OMON46971HagaZiekenhuis12
Active, not recruiting
Phase 1
The influence of cytochrome P450 3A4 inhibitors on serum levels of Ivacaftor in cystic fibrosis patients and healthy subjects.cystic fibrosis and healthy subjectsEUCTR2016-001440-18-NLuniversity medical center utrecht12